RT Journal Article SR Electronic T1 PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2501 OP 2509 DO 10.21873/anticanres.15028 VO 41 IS 5 A1 KAKERU HISAKANE A1 MASAHIRO SEIKE A1 TEPPEI SUGANO A1 KUNIKO MATSUDA A1 SHINOBU KUNUGI A1 SHINJI NAKAMICHI A1 MASARU MATSUMOTO A1 AKIHIKO MIYANAGA A1 RINTARO NORO A1 YUJI MINEGISHI A1 KAORU KUBOTA A1 AKIHIKO GEMMA YR 2021 UL http://ar.iiarjournals.org/content/41/5/2501.abstract AB Background/Aim: Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive tumor that is resistant to treatment. The expression and prognostic value of programmed cell death-ligand 1 (PD-L1) and its association with epithelial–mesenchymal transition (EMT) in PPC remains unclear. Patients and Methods: The expression of PD-L1 and EMT markers, such as E-cadherin, vimentin, zinc finger E-box-binding homeobox 1 (ZEB-1), and cellular mesenchymal–epithelial transition (c-Met) was evaluated by immuno - histochemistry in 16 patients with PPC who underwent surgical resection. Results: The expression of PD-L1 varied between carcinomatous and sarcomatous areas. Positive correlations between PD-L1 and vimentin expression in carcinomatous areas (r=0.668, p=0.005) and PD-L1 and ZEB-1 expression in sarcomatous areas (r=0.562, p=0.023) were found. High PD-L1 and ZEB-1 expression in sarcomatous areas predicted poor survival (p=0.045 and p=0.012, respectively). Conclusion: PD-L1 expression associated with ZEB1 expression in the sarcomatoid component of patients with PPC may be useful for predicting patient prognosis.